<DOC>
	<DOCNO>NCT01328457</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness treatment PMIM patient visceral leishmaniasis within VL-endemic region Bangladesh EOT ( 21/22 day treatment begin ) , 6 month end treatment ( Day 202/203 , -15 +30 day ) .</brief_summary>
	<brief_title>An Effectiveness Study Paromomycin IM Injection ( PMIM ) Treatment Visceral Leishmaniasis ( VL ) Bangladesh</brief_title>
	<detailed_description>Safe , effective affordable treatment visceral leishmaniasis ( VL ) widely available poor population urgently need Bangladesh area disease endemic . Paromomycin IM Injection ( PMIM ) approve treatment VL August 2006 Drugs Controller General India ( DCGI ) , offer attractive alternative treatment currently available .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<criteria>1 . Signs symptom VL include : History intermittent fever least two week History weight loss and/or decrease appetite Enlarged spleen 2 . VL serologically confirm use rK39 test : 3 . Willingness / ability understand provide inform consent prior participation study : 4 . Age ≥ five year ≤ 55 year , weigh least five kg 5 . Adequately hydrate assessed clinical criterion able maintain adequate hydration outpatient basis oral intake fluid 6 . Clinically stable appropriate treatment PMIM outpatient , possible ( subject may hospitalize receive 21day dose discretion investigator ) 7 . Living VLendemic area Bangladesh 1 . Active tuberculosis take antituberculosis medication 2 . Previous treatment Paromomycin IM Injection ( PMIM ) 3 . Clinically significant severe anemia determine investigator 4 . Clinically significant renal hepatic dysfunction determine investigator , history clinically significant renal hepatic dysfunction 5 . History Hepatitis B C ; know HIV positive 6 . History hearing loss 7 . Other serious illness medical condition , opinion doctor , would interfere patient 's ability receive PMIM treatment comply study procedure , could obscure toxicity response PMIM 8 . Major surgery within 30 day prior first dose PMIM 9 . History hypersensitivity aminoglycosides component PMIM , include sulfite 10 . Any history VL treatment VL time 11 . Patients receive investigational ( unlicensed ) drug within last six month 12 . Concomitant use aminoglycosides ( e.g. , gentamicin , tobramycin , amikacin ) , nephrotoxic ototoxic drug , immunosuppressive drug 13 . Proteinuria ( result &gt; 1+ ) urine dipstick analysis screen visit and/or 14 . Serum creatinine upper limit normal ( ie , serum creatinine &gt; 1.1 mg/dl male &gt; 0.9 mg/dl female 15 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Leishmaniasis , Visceral</keyword>
	<keyword>kala-azar</keyword>
	<keyword>Paromomycin</keyword>
	<keyword>Bangladesh</keyword>
	<keyword>Injections , Intramuscular</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Patient compliance</keyword>
	<keyword>Medication adherence</keyword>
	<keyword>Drug toxicity</keyword>
</DOC>